Navigation Links
ATTO-TAG CBQCA Amine-Derivatization Kit from Molecular Probes (Invitrogen)

ProductsATTO-TAG CBQCA Amine-Derivatization Kit from Molecular Probes (Invitrogen)
Company Molecular Probes (Invitrogen)
Item ATTO-TAG CBQCA Amine-Derivatization Kit
Price 
Description Molecular Probes is pleased to offer the ATTO-TAG series of reagents for the ultrasensitive detection of primary amines. Developed by Novotny and collaborators at Indiana University, the ATTO-TAG reagents are similar to the important reagents o-phthaldialdehyde (OPA), naphthalene-2,3-dicarboxaldehyde (NDA) and anthracene-2,3-dicarboxaldehyde, all of which are also available in high purity form from Molecular Probes.

Principle:
ATTO-TAG CBQCA (3-(4-carboxybenzoyl)quinoline-2-carboxaldehyde or CBQCA 1) and ATTO-TAG FQ (3-(2-furoyl) quinoline-2-carboxaldehyde 2) react specifically with primary amines to form conjugates that can be analyzed by electrophoretic or chromatographic methods. Unlike OPA and NDA, ATTO-TAG CBQCA will also react with hydrophilic peptides and amino sugars. The resulting products of CBQCA highly fluorescent 7-aza-1-cyano-5,6-benzisoindoles are maximally excited at 450nm or by the 442 nm spectral line of the He-Cd laser and have emission maxima at ~550 nm. The products of ATTO-TAG FQ are maximally excited at 480 nm or by the 488 nm line of the argon-ion laser and have emission maxima at ~590 nm. In capillary zone electrophoresis (CZE), the sensitivity of detection of ATTO-TAG CBQCA conjugates should be in the attomole range (10-18 moles). The high sensitivity, freedom from background and long-wavelength excitability make these potential reagents for research, diagnostic and forensic applications, including drug analysis. The ATTO-TAG reagents can, of course, be used in HPLC and other modes of chromatography with either absorbance or fluorescence detection. The principal limitation to obtaining ultrasensitive detection using chemical derivatization reagents, including the ATTO-TAG reagents, is that relatively high concentrations of the derivatizing reagent are required to obtain adequate kinetics and sufficient modification of the analyte. A recently described technique employs ATTOTAG FQ for the solid-phase derivatization of dilute solutions (10-8 M) of peptides that have been immobilized on Immobilon-CD membranes. This method permits the quantitative derivatization and analysis by capillary electrophoresis of only a few picomoles of the analyte.
Info Molecular Probes (Invitrogen)Molecular Probes (Invitrogen)
PO Box 22010
Eugene, OR 97402-0469

Call Molecular Probes (Invitrogen) to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-541-359-2658
Customer Service: 1-541-465-8300
Fax Number: 1-541-344-6504
Web Site: http://probes.invitrogen.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. ATTO-TAG FQ Amine-Derivatization Kit from Molecular Probes (Invitrogen)
2. ATTO-TAG CBQCA derivatization reagent (CBQCA; 3-(4-carboxybenzoyl)quinoline-2-carboxaldehyde) from Molecular Probes (Invitrogen)
3. Cleland’s Reagent, Molecular Biology Grade from Calbiochem
4. SYBR Green II RNA gel stain*10,000X concentrate in DMSO* from Molecular Probes (Invitrogen)
5. SYBR Green II RNA gel stain*10,000X concentrate in DMSO* from Molecular Probes (Invitrogen)
6. SYBR Green II RNA gel stain*10,000X concentrate in DMSO**special packaging* from Molecular Probes (Invitrogen)
7. AquaMax DW4 from Molecular Devices
8. GenePix Pro Microarray Image Analysis Software from Molecular Devices
9. adenosine 5-O-(3-thiotriphosphate), BODIPY FL conjugated/tagged from Molecular Probes (Invitrogen)
10. Acuity Enterprise Microarray Informatics Software from Molecular Devices
11. SlowFade Antifade Kit from Molecular Probes (Invitrogen)
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Biology Products:
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... LOS ANGELES , March 23, 2015  In ... in Federal fraud case conviction losses. This figure accounts ... fraud, which, according to The Nilson Report, exceeds $11 ... an investigative tool after a crime has occurred. Investor ... Agent and polygraph expert Joe Paolella partnered ...
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... Liverpool are developing a new plant-based product that could replace fishmeal, ... at a time when more than 90% of EU waters are ... to satisfy consumer need for fish in an expanding human population, ... 1.9 million tonnes by 2035. Currently farmed fish, such ...
... , AURORA, Colo. (May 14, 2012) - Why does ... published by a University of Colorado School of Medicine researcher ... anorexic women and desensitized in obese women. The findings also ... involved in addictions. Guido Frank, MD, assistant professor ...
... out scientifically valid virtual experiments. The method yields insights ... to research from the University of Gothenburg, Sweden. ... from the Swedish town of Lysekil for one year. ... Inquiry to Insight., Using scientific data provided by the ...
Cached Biology News:New product to replace fishmeal could help prevent global food shortage 2Real science in virtual school labs 2
(Date:3/30/2015)... N.J. , March 30, 2015  New Jersey ... innovation projects in the state of New ... next round of grant funding, announced James M. ... Jersey Health Foundation Research Grants program, an additional $500,000 ... each to fund early stage research projects that demonstrate ...
(Date:3/30/2015)... , March 30, 2015 CASI Pharmaceuticals, ... to the acquisition, development and commercialization of innovative therapeutics ... global market with a commercial focus on ... and Drug Administration (CFDA) has approved the Company,s application ... ovarian clear cell carcinoma (OCCC) patients for its proprietary ...
(Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
(Date:3/30/2015)... (PRWEB) March 29, 2015 A two-day ... United States and plenary talks by four leading photonics ... Optics + Optoelectronics next month in Prague, Czech ... in 17 conferences alongside a two-day exhibition. Sponsored by ... , the event will run 13-16 April in the ...
Breaking Biology Technology:New Jersey Health Foundation Announces An Additional $1 Million To Fund Innovation and Research Grants in New Jersey 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3